In this episode of OncoDaily, host Sergey Badalyan is joined by Dr. Aaron R. Sasson, Professor of Surgery, Chief of the Division of Surgical Oncology, and Director of the Pancreatic Cancer Center at Stony Brook Medicine, to discuss a major milestone in pancreatic cancer treatment — the FDA approval of OptumPax.
This first-of-its-kind device introduces a non-invasive, electricity-based approach that disrupts cancer cell division. While not curative, it represents an important new option for patients who are not candidates for surgery.
The conversation explores how this therapy works, its clinical significance, and where it fits within current treatment strategies alongside chemotherapy. Dr. Aaron R. Sasson also highlights the impact on quality of life, pain control, and the challenges of accessibility and patient adherence.
This discussion provides valuable insights into how innovation is shaping the future of care for patients worldwide.